Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model

It was reported that cilostazol (CLZ) suppressed disruption of the microvasculature in ischemic areas. In this study, we have designed novel injection formulations containing CLZ nanoparticles using 0.5% methylcellulose, 0.2% docusate sodium salt, and mill methods (CLZnano dispersion; particle size 81 ± 59 nm, mean ± S.D.), and investigated their toxicity and usefulness in a cerebral ischemia/reperfusion-induced injury model (MCAO/reperfusion mice). The pharmacokinetics of injections of CLZnano dispersions is similar to that of CLZ solutions prepared with 2-hydroxypropyl-β-cyclodextrin, and no changes in the rate of hemolysis of rabbit red blood cells, a model of cell injury, were observed with CLZnano dispersions. In addition, the intravenous injection of 0.6 mg/kg CLZnano dispersions does not affect the blood pressure and blood flow, and the 0.6 mg/kg CLZnano dispersions ameliorate neurological deficits and ischemic stroke in MCAO/reperfusion mice. It is possible that the CLZnano dispersions will provide effective therapy for ischemic stroke patients, and that injection preparations of lipophilic drugs containing drug nanoparticles expand their therapeutic usage.

[1]  Y. Kimura,et al.  Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. , 1999, Thrombosis research.

[2]  Y. Kimura,et al.  Effect of cilostazol, a new antithrombotic drug, on cerebral circulation. , 1985, Arzneimittel-Forschung.

[3]  I. Lucet,et al.  Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. , 1996, Journal of microencapsulation.

[4]  Kortaro Tanaka,et al.  Effects of a selective inhibitor of cyclic AMP phosphodiesterase on the pial microcirculation in feline cerebral ischemia. , 1989, Stroke.

[5]  H. Shin,et al.  Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. , 2002, The Journal of pharmacology and experimental therapeutics.

[6]  A. Go.  The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. , 2005, The American journal of geriatric cardiology.

[7]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[8]  J. H. Lee,et al.  Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats , 2005, Neurological research.

[9]  P. Chan,et al.  Role of the p38 Mitogen-Activated Protein Kinase/Cytosolic Phospholipase A2 Signaling Pathway in Blood—Brain Barrier Disruption after Focal Cerebral Ischemia and Reperfusion , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  K. Kataoka,et al.  Block copolymer micelles for drug delivery: design, characterization and biological significance. , 2001, Advanced drug delivery reviews.

[11]  K. Kitagawa,et al.  Cilostazol, Not Aspirin, Reduces Ischemic Brain Injury via Endothelial Protection in Spontaneously Hypertensive Rats , 2011, Stroke.

[12]  C. Kim,et al.  Cilostazol Prevents Focal Cerebral Ischemic Injury by Enhancing Casein Kinase 2 Phosphorylation and Suppression of Phosphatase and Tensin Homolog Deleted from Chromosome 10 Phosphorylation in Rats , 2004, Journal of Pharmacology and Experimental Therapeutics.

[13]  D. Stern,et al.  Cilostazol Reduces the Risk of Hemorrhagic Infarction After Administration of Tissue-Type Plasminogen Activator in a Murine Stroke Model , 2012, Stroke.

[14]  Y. Shimomura,et al.  A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability. , 2014, Toxicology.

[15]  Parag Aggarwal,et al.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. , 2008, Molecular pharmaceutics.

[16]  A. Dávalos,et al.  Progression of ischaemic stroke and excitotoxic aminoacids , 1997, The Lancet.

[17]  Yoshiaki,et al.  Further Application of a Modified Spontaneous Emulsification Solvent Diffusion Method to Various Types of PLGA and PLA Polymers for Preparation of Nanoparticles. , 2000 .

[18]  R. Morishita,et al.  Particle size control of poly(dl-lactide-co-glycolide) nanospheres for sterile applications. , 2009, International journal of pharmaceutics.

[19]  C. Ríos,et al.  Metallothionein-II Inhibits Lipid Peroxidation and Improves Functional Recovery after Transient Brain Ischemia and Reperfusion in Rats , 2014, Oxidative medicine and cellular longevity.

[20]  D. Begley.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[21]  Y. Shimomura,et al.  A nanoparticle formulation of disulfiram prolongs corneal residence time of the drug and reduces intraocular pressure. , 2015, Experimental eye research.

[22]  H. Hansson,et al.  Gel Matrix Vehicles for Growth Factor Application in Nerve Gap Injuries Repaired with Tubes: A Comparison of Biomatrix, Collagen, and Methylcellulose , 1997, Experimental Neurology.

[23]  T. Iwama,et al.  Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage , 2009, Neuroscience Letters.

[24]  K. Matsumoto,et al.  Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[25]  O. Mimura,et al.  Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea. , 2010, Journal of oleo science.

[26]  S. Cuzzocrea,et al.  Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. , 2001, Pharmacological reviews.

[27]  Yongge Liu,et al.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. , 2006, Cardiovascular drug reviews.

[28]  Charles H Tator,et al.  Fast-gelling injectable blend of hyaluronan and methylcellulose for intrathecal, localized delivery to the injured spinal cord. , 2006, Biomaterials.

[29]  M. Moskowitz,et al.  Reduced Brain Edema and Infarction Volume in Mice Lacking the Neuronal Isoform of Nitric Oxide Synthase after Transient MCA Occlusion , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  H. Hara,et al.  Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2 , 2006, Brain Research.

[31]  C. Kim,et al.  Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury , 2008, CNS neuroscience & therapeutics.

[32]  T. Iwama,et al.  Phosphodiesterase-III Inhibitor Prevents Hemorrhagic Transformation Induced by Focal Cerebral Ischemia in Mice Treated with tPA , 2010, PloS one.

[33]  Y. Funakami,et al.  Effects of some beta-adrenoceptor antagonists on orthostatic hypotension in repeatedly cold- (SART-) stressed rats. , 2007, Biological & pharmaceutical bulletin.

[34]  Yasuo Ikeda,et al.  Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. , 1997, Life sciences.

[35]  R. Takahashi,et al.  Cilostazol alleviates cerebral small-vessel pathology and white-matter lesions in stroke-prone spontaneously hypertensive rats , 2008, Brain Research.

[36]  S. Papson,et al.  “Model” , 1981 .

[37]  Efstathios Karathanasis,et al.  Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles. , 2014, Nanomedicine.

[38]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[39]  S. Thomas Carmichael,et al.  Rodent models of focal stroke: Size, mechanism, and purpose , 2005, NeuroRX.

[40]  T. Tani,et al.  Effect of cilostazol on platelet aggregation and experimental thrombosis. , 1985, Arzneimittel-Forschung.